Genzyme, Daiichi Try To Halt Impax’s Generic Welchol

Law360, New York (January 15, 2010, 4:59 PM EST) -- Genzyme Corp. and Daiichi Sankyo Inc. have dragged Impax Laboratories to court in an effort to block it from marketing a generic version of their cholesterol drug Welchol.

After learning of Impax’s plans to release the generic, Genzyme and Daiichi filed a lawsuit Thursday in the U.S. District Court for the District of Delaware for patent infringement.

Welchol, sold in 625 mg colesevelem hydrochloride tablets, is currently approved to treat high cholesterol and to help lower blood glucose for patients with type 2 diabetes mellitus....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.